ES2134804T3 - Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal. - Google Patents
Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.Info
- Publication number
- ES2134804T3 ES2134804T3 ES92910911T ES92910911T ES2134804T3 ES 2134804 T3 ES2134804 T3 ES 2134804T3 ES 92910911 T ES92910911 T ES 92910911T ES 92910911 T ES92910911 T ES 92910911T ES 2134804 T3 ES2134804 T3 ES 2134804T3
- Authority
- ES
- Spain
- Prior art keywords
- neuronal damage
- mammal
- nitric oxide
- generator compound
- prevent neuronal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Abstract
SE PRESENTA UN MEDICAMENTO PARA REDUCIR LOS DAÑOS NEURONALES MEDIATIZADOS POR EL RECEPTOR DEL NMDA EN LOS MAMIFEROS, QUE COMPRENDE UN COMPUESTO GENERADOR DE OXIDO NITRICO, O UNA SAL FARMACOLOGICAMENTE ACEPTABLE DEL MISMO, EN UNA CONCENTRACION EFECTIVA PARA PROVOCAR DICHA REDUCCION. TAMBIEN SE PRESENTA UN MEDICAMENTO PARA REDUCIR LOS DAÑOS NEURONALES MEDIATIZADOS POR EL RECEPTOR DEL NMDA EN LOS MAMIFEROS QUE COMPRENDE NITROPRUSURO, NITROGLICERINA, O UN DERIVADO DE UNO DE ESTOS COMPUESTOS, EN UNA CONCENTRACION EFECTIVA PARA PROVOCAR DICHA REDUCCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68896591A | 1991-04-19 | 1991-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2134804T3 true ES2134804T3 (es) | 1999-10-16 |
Family
ID=24766524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92910911T Expired - Lifetime ES2134804T3 (es) | 1991-04-19 | 1992-04-17 | Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5234956A (es) |
EP (1) | EP0581856B1 (es) |
JP (2) | JPH06506690A (es) |
AT (1) | ATE182076T1 (es) |
DE (1) | DE69229598T2 (es) |
ES (1) | ES2134804T3 (es) |
WO (1) | WO1992018112A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721365A (en) * | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US6071876A (en) * | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
CA2148484A1 (en) * | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
DE4305881C1 (de) * | 1993-02-26 | 1994-03-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung |
US5475007A (en) * | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
US5840759A (en) * | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
DE69425331D1 (de) * | 1993-10-08 | 2000-08-24 | Us Health | Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
CA2132690A1 (en) * | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
US20050137191A1 (en) * | 1996-06-04 | 2005-06-23 | Thatcher Gregory R. | Nitrate esters and their use for mitigating cellular damage |
US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
ES2483126T3 (es) | 2004-06-17 | 2014-08-05 | Merz Pharma Gmbh & Co. Kgaa | Formulaciones de formas de dosificación de neramexano |
EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
WO2009152483A2 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma |
WO2009152479A1 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases of trauma |
MX2012008514A (es) | 2010-01-27 | 2012-08-17 | Takeda Pharmaceutical | Compuesto para suministrar transtorno de nervio periferico inducido por agente anticancerigeno. |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
AU2018230478A1 (en) | 2017-03-09 | 2019-09-12 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
WO1991002810A1 (en) * | 1989-08-09 | 1991-03-07 | The Children's Medical Center Corporation | Nmda oxidizing agents for protecting neurons from injury |
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
-
1992
- 1992-04-17 JP JP4510067A patent/JPH06506690A/ja active Pending
- 1992-04-17 WO PCT/US1992/003196 patent/WO1992018112A1/en active IP Right Grant
- 1992-04-17 EP EP92910911A patent/EP0581856B1/en not_active Expired - Lifetime
- 1992-04-17 ES ES92910911T patent/ES2134804T3/es not_active Expired - Lifetime
- 1992-04-17 DE DE69229598T patent/DE69229598T2/de not_active Expired - Lifetime
- 1992-04-17 AT AT92910911T patent/ATE182076T1/de active
- 1992-09-22 US US07/949,342 patent/US5234956A/en not_active Expired - Lifetime
-
2005
- 2005-12-16 JP JP2005362538A patent/JP2006117693A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE182076T1 (de) | 1999-07-15 |
DE69229598D1 (de) | 1999-08-19 |
JPH06506690A (ja) | 1994-07-28 |
DE69229598T2 (de) | 1999-11-04 |
EP0581856A4 (es) | 1994-03-02 |
US5234956A (en) | 1993-08-10 |
EP0581856A1 (en) | 1994-02-09 |
JP2006117693A (ja) | 2006-05-11 |
WO1992018112A1 (en) | 1992-10-29 |
EP0581856B1 (en) | 1999-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2134804T3 (es) | Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal. | |
AU5348194A (en) | Method of preventing nmda receptor complex-mediated neuronal damage | |
ES2148223T3 (es) | Taxol encapsulado en liposomas y metodo para su uso. | |
MX9204268A (es) | Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma. | |
ES2114931T3 (es) | Nuevos esteres esteroidales. | |
ES2055406T3 (es) | Composicion para el tratamiento de la inflamacion. | |
ES2059121T5 (es) | Uso de agentes sensibilizantes de la insulina para tratar la hipertension. | |
ES2051650A1 (es) | Procedimiento para preparar un limpiador de oxigeno activo. | |
ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
ES2136252T3 (es) | Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa. | |
ES2167931T3 (es) | Derivados bifenilicos sustituidos por un radical aromatico o heteroaromatico y composiciones farmaceuticas y cosmeticas que los contienen. | |
ES2193233T3 (es) | Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica. | |
ES2058596T3 (es) | Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso. | |
RU94031161A (ru) | Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов | |
SE8004965L (sv) | Anvendningen av rifamycin sv och salter derav vid behandling av reumatoid artrit och beredningar derav lempade for endamalet | |
NO923200D0 (no) | Piperidin-derivater | |
DK0588796T3 (da) | Sampanginderivater til anvendelse som antifungiske og antimykobakterielle midler | |
JPS5256A (en) | Sediment-contained water treating method | |
SE7501002L (es) | ||
ES2187534T3 (es) | Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida. | |
ES2010161A4 (es) | Utilizacion de una mezcla para el tratamiento de la alopecia | |
ES2084878T3 (es) | Sal colina de diclofenac, un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
ATE82850T1 (de) | Verwendung von 2-pyrimidinyl-1-piperazinderivaten. | |
IT1238356B (it) | Derivati gangliosidici, loro uso quali agenti terapeutici, procedimento per la loro produzione e composti farmaceutici che li contengono. | |
DK218388A (da) | Aktivt princip isoleret fra hajvaev |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 581856 Country of ref document: ES |